In Nature this week: circular consensus sequencing method to sequence and assemble a human genome, a new CRISPR platform using the Cpf1 endonuclease, and more.
The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.
As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
